Clinical Trial: NCT02858258
ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma
Status:
UNKNOWNPhase:
Phase 3| Lead Sponsor: | Prof. Dr. M. Dreyling (co-chairman) |
| Information Provided By: | European Mantle Cell Lymphoma Network |
| Last Update Posted: | 2017-12-19 |
Study Overview
Brief Summary
The primary objective of the the trial is to establish one of three study arms, as future standard based on the comparison of the investigator-assessed failure-free survival.
Official Title
Autologous Transplantation After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma - a Randomized European Mcl Network Trial
Conditions
Mantle Cell Lymphoma
Intervention / Treatment
- Drug: R-CHOP/R-DHAP
- Drug: Ibrutinib (Induction)
- Drug: ASCT conditioning
- Drug: Ibrutinib (Maintenance)
Other Study ID Numbers
- TRIANGLE
Start Date
2016-07
Primary Completion Date (Estimated)
2021-05
Study Completion Date (Estimated)
2026-05
Enrollment (Estimated)
870
Study Type
Interventional
Phase
Phase 3
| Lead Sponsor: | Prof. Dr. M. Dreyling (co-chairman) |
| Information Provided By: | European Mantle Cell Lymphoma Network |
| Last Update Posted: | 2017-12-19 |
Study Overview
Brief Summary
The primary objective of the the trial is to establish one of three study arms, as future standard based on the comparison of the investigator-assessed failure-free survival.
Official Title
Autologous Transplantation After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma - a Randomized European Mcl Network Trial
Conditions
Mantle Cell Lymphoma
Intervention / Treatment
- Drug: R-CHOP/R-DHAP
- Drug: Ibrutinib (Induction)
- Drug: ASCT conditioning
- Drug: Ibrutinib (Maintenance)
Other Study ID Numbers
- TRIANGLE
Start Date
2016-07
Primary Completion Date (Estimated)
2021-05
Study Completion Date (Estimated)
2026-05
Enrollment (Estimated)
870
Study Type
Interventional
Phase
Phase 3